Overview

Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer

Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen. Combination chemotherapy uses different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of tamoxifen with or without chemotherapy and/or ovarian ablation in treating women with stage I, stage II, or stage IIIA breast cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Institute of Cancer Research, United Kingdom
Collaborators:
Cancer Research Campaign Clinical Trials Centre
Scottish Cancer Therapy Network
Yorkshire Regional Clinical Trials Research Unit
Treatments:
Cyclophosphamide
Doxorubicin
Fluorouracil
Goserelin
Leuprolide
Liposomal doxorubicin
Methotrexate
Tamoxifen